incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Sudanese Sovereignty Council (1955–1958) Armed Forces Supreme Council (Sudan) (1958–1964); see 1958 Sudanese coup d'état Sudanese Sovereignty Council (1964–1965) Sudanese Sovereignty Council (1965–1969) National Revolutionary Command Council (Sudan) (1969–1971) Transitional Military Council (1985) (1985–1986) Transitional Military Council (2019) Transitional Sovereignty Council (2019–2021, 2021–present)
During the 1970s, the expansion of Arby's took place at a rate of 50 stores per year. During this time it created several menu items, including the Beef 'n Cheddar, Jamocha Shakes, chicken sandwiches, curly fries, and two signature sauces: Arby's Sauce and Horsey Sauce. Baked potatoes were added to the menu in 1985. Curly fries were initially introduced as Curly-Q Fries in 1988. It became the first restaurant in the fast food industry to offer a complete "lite" menu in 1991 with several sandwiches and salads under 300 calories and 94 percent fat-free. The family-owned business tried converting into a public company in 1970 by offering the sale of stock, but the IPO never went through when the stock market subsequently fell. Arby's filed for reorganization with the United States bankruptcy court in February 1971, owing to a large number of debts accrued in expansion, as well as a nationwide recession and relatively high price point compared to other fast-food chains of the time. In 1976, the family sold the company to RC Cola for $18 million and Leroy Raffel remained as CEO until his retirement three years later. In 1984, Victor Posner obtained Arby's via a hostile takeover of its then parent Royal Crown through his DWG Corporation. Nine years later, with a new owner of DWG Corporation and a new name, Triarc Companies, Inc., a former PepsiCo executive, Don Pierce, was brought in to "resurrect" Arby's. With $100 million additional funding, Pierce moved to a new "Roast Town" concept, similar in format to Boston Market, in 1996.
Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and was among the 40 largest in the world by revenue in 2012. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.
Sources: en.wikipedia.org
=== Cancer === After finding that Ras proteins are mutated in 30% of human cancers, it was suspected that mutated Rho proteins might also be involved in cancer reproduction. However, as of August 2007, no oncogenic mutations have been found in Rho proteins, and only one has been found to be genetically altered. To explain the role of Rho pathways without mutation, researchers have now turned to the regulators of rho activity and the levels of expression of the Rho proteins for answers. One way to explain altered signaling in the absence of mutation is through increased expression. Overexpression of RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, RhoE, RhoG, RhoH, and Cdc42 has been shown in multiple types of cancer. This increased presence of so many signaling molecules implies that these proteins promote the cellular functions that become overly active in cancerous cells. A second target to explain the role of the Rho proteins in cancer is their regulatory proteins. Rho proteins are very tightly controlled by a wide variety of sources, and over 60 activators and 70 inactivators have been identified. Multiple GAPs, GDIs, and GEFs have been shown to undergo overexpression, downregulation, or mutation in different types of cancer. Once an upstream signal is changed, the activity of its targets downstream—i.e., the Rho proteins—will change in activity. Ellenbroek et al. outlined a number of different effects of Rho activation in cancerous cells. First, in the initiation of the tumor modification of Rho activity can suppress apoptosis and therefore contribute to artificial cell longevity.
=== Diet === In the wild, the croaking gourami is mostly insectivorous, feeding on insects and insect larvae. However, other food types, such as zooplankton, crustaceans, shrimp meat and plant matter, are eaten as well. In aquaria, a varied diet is recommended: standard flake foods along with regular supplements of freeze-dried bloodworms, tubifex worms, brine shrimp, and some algae-based flakes will provide the fish with proper nutrition. Occasional feedings of live brine shrimp offer the aquarist an opportunity to observe the natural hunting behaviour of this species.
The new owner of the Wilko brand announces that up to five shops will open under the Wilko name before Christmas. GB News hires former prime minister Boris Johnson to present a series "showcasing the power of Britain around the world"; he will also help to provide coverage of the next UK and US elections. Data released to BBC News indicates there are around 3,500 dogs belonging to banned species living legally at residences in the UK mainland under an exemption scheme. 28 October – £10 million worth of cocaine is found in a Panamanian-registered container ship carrying bananas to the Netherlands at the Port of Sheerness. 30 October The UK government grants 27 new oil and gas licences for projects in the North Sea that will allow potential resources to be explored and developed. Mark Drakeford, First Minister of Wales and leader of Welsh Labour, echoes Labour leader Sir Keir Starmer's call for a humanitarian pause in the Gaza conflict to allow aid in to the region. His comments come after 12 of his backbenchers in the Senedd signed a petition calling for a ceasefire. Joshua Bowles, a former GCHQ employee from Cheltenham, who stabbed a woman from the US in a March 2023 attack at a leisure centre car park in the town, is sentenced to life imprisonment with a minimum of 13 years after pleading guilty to attempted murder at an Old Bailey hearing. The Met Office issues a warning for heavy rain and floods for parts of the UK ahead of the arrival of Storm Ciarán.
=== Proteogenomics === In proteogenomics, proteomic technologies such as mass spectrometry are used for improving gene annotations. Parallel analysis of the genome and the proteome facilitates discovery of post-translational modifications and proteolytic events, especially when comparing multiple species (comparative proteogenomics).
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.